The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges

AXL, along with MER and TYRO3, is a receptor tyrosine kinase from the TAM family. Although AXL itself is not thought to be a potent oncogenic driver, overexpression of AXL is known to trigger tumor cell growth, survival, invasion, metastasis, angiogenesis, epithelial to mesenchymal transition, and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sang, Yun Beom, Kim, Joo-Hang, Kim, Chang-Gon, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul, Lim, Sun Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927964/
https://www.ncbi.nlm.nih.gov/pubmed/35311091
http://dx.doi.org/10.3389/fonc.2022.811247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927964/
https://www.ncbi.nlm.nih.gov/pubmed/35311091
http://dx.doi.org/10.3389/fonc.2022.811247

Ejemplares similares